Volume | 747,153 |
|
|||||
News | - | ||||||
Day High | 2.045 | Low High |
|||||
Day Low | 1.98 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Esperion Therapeutics Inc | ESPR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.0401 | 1.98 | 2.045 | 2.13 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,557 | 747,153 | $ 2.01 | $ 1,501,174 | - | 0.70 - 3.40 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
10:05:35 | 3 | $ 1.995 | USD |
Esperion Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
375.66M | 185.05M | - | 116.33M | -209.25M | -1.13 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Esperion Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ESPR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.86 | 2.16 | 1.71 | 1.98 | 5,707,369 | 0.13 | 6.99% |
1 Month | 2.64 | 3.40 | 1.71 | 2.57 | 7,841,377 | -0.65 | -24.62% |
3 Months | 2.16 | 3.40 | 1.71 | 2.51 | 6,376,767 | -0.17 | -7.87% |
6 Months | 0.814 | 3.40 | 0.706 | 2.25 | 5,998,050 | 1.18 | 144.47% |
1 Year | 1.21 | 3.40 | 0.70 | 1.92 | 4,581,747 | 0.78 | 64.46% |
3 Years | 27.59 | 28.75 | 0.70 | 3.82 | 2,641,541 | -25.60 | -92.79% |
5 Years | 41.87 | 79.989 | 0.70 | 8.75 | 1,826,076 | -39.88 | -95.25% |
Esperion Therapeutics Description
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. |